Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia (NVG-LIGHT)
International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease
Sponsor: Artgen Biotech
A PHASE4 clinical study on Lower Limb Ischemia, this trial is completed. The trial is conducted by Artgen Biotech and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Jul 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed · Phase: NA → PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Artgen Biotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barnaul, Russia , Blagoveshchensk, Russia , Chelyabinsk, Russia , Chita, Russia , Irkutsk, Russia , Kazan', Russia , Kemerovo, Russia , Khabarovsk, Russia , Krasnodar, Russia , Krasnoyarsk, Russia and 17 more locations